Vertex Pharmaceuticals Incorporated Q3 2026 Earnings Recap

Shares fell 4.0% after earnings, with investors likely focused on the lack of a clear path to pivotal development for Vertex’s next-generation CF candidate VX-828: results showed benefit only in the triple combination, and the company plans to wait for data from the broader program before deciding next steps. The quarter’s 12% revenue growth and pipeline progress were positives, but the transcript does not provide updated financial guidance or enough detail to identify another specific source of disappointment.

Key Takeaways

• Third-quarter revenue grew 12% year over year, with contributions from the U.S. and international markets, CF, CASGEVY, JOURNAVX, and PALSONIFY for September.
• In a small VX-828 study among 16 people with CF and FMF mutations, the dual combination did not change sweat chloride versus the Trikafta baseline; the triple combination reduced it by 6.6 mmol/L at day 28. Vertex will wait for data from other next-generation candidates before deciding whether to advance the program into pivotal development.
• Vertex said it had recently received CASGEVY approvals for patients ages 2–11 in the U.S., UAE, and Bahrain, and ages 5–11 in the U.K.
• Enrollment in both phase 3 JOURNAVX studies for painful diabetic peripheral neuropathy remains on track to finish by year-end, with results expected by mid-2027.
• Enrollment in the phase 3 adult CAH study of atumelnant is targeted for completion in Q1 2027; the trial includes 32 weeks of dosing.